Launch

Symbiotec's $190M IPO debuts flat after 75x demand

What's the deal? Symbiotec Pharmalab listed at US$13.4 per share on September 1, 2026, matching its issue price after a US$238.6M IPO that drew bids 75.06 times the shares on offer. The Indore-based pharmaceutical and biotechnology company debuted on both BSEDealroom has a profile for this one. Try Dealroom → and NSE.

What's inside the offer? The issue combined a US$20.4M fresh raise with a US$218.2M offer for sale, meaning most proceeds went to selling shareholders rather than the company. Sellers included Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund - III.

Why now? The book-built offer ran from August 24 to August 27, pricing at the top of its US$12.7 to US$13.4 band. Despite heavy subscription demand, the stock opened flat — neither premium nor discount — against pre-issue grey-market chatter.

By the numbers: Symbiotec reported US$118.5M in revenue and US$14.9M profit in 2026, up from US$102.7M and US$13.1M a year earlier. That marks a US$15.8M revenue gain and a US$1.78M rise in profit.

Who ran it? JM FinancialDealroom has a profile for this one. Try Dealroom →, Avendus CapitalDealroom has a profile for this one. Try Dealroom →, Motilal Oswal Investment Advisors, and Nomura Financial Advisory served as book-running lead managers, with MUFG Intime India as registrar.

The signal: Symbiotec, which specialises in API manufacturing and regulatory-approved biotech work, lands in a contract development and manufacturing market projected to grow at an 8.2% CAGR. Its flat debut amid a busy late-August IPO calendar shows strong institutional appetite can still coexist with cautious opening-day pricing.

Read more: multibagg.ai

Image credit: Symbiotec Pharmalab

More top stories